Faculty
|
| |
Profile |
|
| |
Dr. Abimiku is trained in Medical Microbiology with specialization in Virology and Immunology during her 4 years postdoctoral training at the Laboratory of Tumor Biology then headed by Dr. Gallo at the National Institutes of Health.
Being originally from Nigeria, Dr. Abimiku pioneers some of the early HIV research in her country. For the last 12 years Dr. Abimiku has implemented HIV surveillance, research, and prevention activities in Nigeria, originally via the ICSC-WL AIDS Research Center in Jos, Nigeria co founded by Dr. Gallo and herself, and more recently as a partner in the Bill and Melinda Gates funded AIDS Prevention Initiative for Nigeria (APIN), coordinated by Harvard University, the US Military-sponsored LIFE program, World AID Foundation, and CDC funded sponsored programs. Integral in these studies is training and technology transfer through a south-to-south collaboration with other African countries especially with The AIDS Support Organization in Uganda.
Dr. Abimiku's ultimate research goal is to epidemiologically characterize selected target study populations in Nigeria for HIV preventative programs including HIV vaccine clinical trails of vaccines developed by the Institute and through the HIV vaccine Trial Network (HVTN).
|
|
| |
Education |
|
| |
•
|
B.S. (honors) - Microbiology, Ahmadu Bello University, Zaria, Nigeria, 1978. |
| • |
M.S. (honors) - Medicine, London School of Hygiene and Tropical Medicine, London, England, 1983. |
|
•
|
Ph.D. - Microbiology, London School of Hygiene and Tropical Medicine, London, England, 1988. |
|
| |
Selected Publications |
|
| |
1. |
Abimiku, A.G. and Dolby, J.M.: The mechanism of protection of infant mice from intestinal colonisation with Campylobacter jejuni. J. Med. Microbiol. 23: 339?344, 1987. |
| |
2. |
Abimiku, A.G. and Dolby, J.M.: Cross?protection of infant mice against intestinal colonisation by Campylobacter jejuni: Importance of heat?labile serotyping (Lior) antigens. J. Med. Microbiol. 26: 265?268, 1988. |
| |
3. |
Abimiku, A.G., Dolby, J.M., and Borriello, S.P.: Comparison of vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse. Epidemiol. Infec. 102: 271?280, 1989. |
| |
4. |
Abimiku, A.G., Dolby, J.M., Borriello, S.P., and Davies, H.: Protection against gastrointestinal colonization by Campylobacter jejuni in the infant mouse model. Microecology and Therapy, 18: 233-239, 1989. |
| |
5. |
Abimiku, A.G. and Borriello, S.P.: Non-colonizing mutant of Campylobacter jejuni: Immuochemical characteristics and efficacy as vaccine in an infant mouse model. Microbial Ecology in Health and Disease 6: 173-180, 1993. |
| |
6. |
Tartaglia, J., Franchini, G., Robert-Guroff, M., Abimiku, A., Benson, J., Limbach, K., Wills, M., Gallo, R.C., and Paoletti, E.: Highly attenuated poxvirus vector strains, NYVAC and ALVAC, in retrovirus vaccines development. In Robert, O. (Ed.): Huitieme Colloque Des Cent Grades - 1993 (Proceedings). Paris, Foundation Merieux, 1993, pp. 293-298. |
| |
7. |
Abimiku, A.G., Zwandor, A., Gomwalk, N., Kyari, S., Opajobi, S., Ibanga, A., Guyit, R., Idoko, J., Anteyi, J., Kigbu, E., Ekezue, E., Danladi, M., Williams, E., Adeniyi-Jones, S., Robert-Guroff, M., and Gallo, R.C.: HIV-1, not HIV-2 is prevalent in Nigeria: Need for consideration in vaccine plans. Vaccine Res. 3: 101-103, 1994. |
| |
8. |
Abimiku, A.G., Stern, T.L., Zwandor, A., Markham, P.D., Calef, C., Kyari, S., Saxinger, W.C., Gallo, R.C., Robert-Guroff, M., and Reitz, M.S.: Subgroup G HIV type 1 isolates from Nigeria. AIDS Res. Hum. Retroviruses 10: 1581-1583, 1994. |
| |
9. |
Abimiku, A.G. and Gallo, R.C.: HIV: Basic virology and pathophysiology. In Minkoff, H.L., DeHovitz, J.A., and Duerr, A. (Eds.): HIV Infection in Women. New York, Raven Press, Ltd., 1995, pp. 13-31. |
| |
10. |
Abimiku, A.G., Franchini, G., Aldrich, K., Myagkikh, M., Markham, P., Gard, E., Gallo, R.C., and Robert-Guroff, M.: Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2. AIDS Res. Hum. Retroviruses 11: 383-393, 1995. |
| |
11. |
Franchini, G., Tartaglia, J., Benson, J., Robert-Guroff, M., Abimiku, A., Paoletti, E., and Gallo, R.C.: NYVAC/ALVAC recombinant vectors as vaccines against HIV-2 and HTLV-I. Proceedings of the Cent Gardes Colloquium - 1994. |
| |
12. |
Franchini, G., Robert-Guroff, M., Tartaglia, J., Aggarwal, A., Abimiku, A.G., Benson, J., Markham, Limbach, K., Hurteau, G., Fullen, J., Aldrich, K., Miller, N., Sadoff, Paoletti, E., and Gallo, R.C.: Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11: 909-920, 1995. |
| |
13. |
Abimiku, A.G., Franchini, G., Tartaglia, J., Aldrich, K., Myagkikh, M., Markham, P., Chong, P., Klein, M., Kieny, M-P., Paoletti, E., Gallo, R.C., and Robert-Guroff, M.: HIV-1 recombinant poxviruses vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Medicine 1: 321-329, 1995. |
| |
14. |
Abimiku, AG., Robert-Guroff, M., Benson, J., Tartaglia, J., Paoletti, E., Gallo, RC., Markham, Phillip., Franchini G.: Long-term survival of SIVmac251-infected macaques previously immunized with NYVAC-SIV vaccines. JAIDS Hum. Retrovirology15: Suppl. 1 S78-S85, 1997 |
| |
15. |
Goa F., Robertson DL., Carruthers CD., Morrison SG., Jain B., Chen Y., Barre-Sinoussi F., Girard M., Srivinasan A., Abimiku A.G., Shaw GM., Sharp PM., Hahn BH. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virology 72: 5680-5698, 1998. |
| |
16. |
Stevceva L., Abimiku AG., Franchinni G. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes and Immunity 1: 308-315, 2000. |
| |
17. |
Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J, Franchini G. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med. 6(10): 1140-1146, 2000. |
| |
18. |
LJ Patterson, B Peng, AG Abimiku, K Aldrick, L Murty, PD Markham, VS Kalyanaraman, WG Alvord. J Tartaglia, G. Franchini, and M Robert-Guroff. Cross-protection in NYVAC-HIV-1 immunized/HIV-2 challenged but not in NYVAC-HIV-3 immunized/SHIV challenged rhesus macaques. AIDS 14: 2445-2455, 2000. |
| |
19. |
Stevceva L., Abimiku AG., Franchinni G. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes and Immunity 1: 308-315, 2000. |
| |
20. |
Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J, Franchini G. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med. 6(10): 1140-1146, 2000. |
| |
21. |
LJ Patterson, B Peng, AG Abimiku, K Aldrick, L Murty, PD Markham, VS Kalyanaraman, WG Alvord. J Tartaglia, G. Franchini, and M Robert-Guroff. Cross-protection in NYVAC-HIV-1 immunized/HIV-2 challenged but not in NYVAC-HIV-3 immunized/SHIV challenged rhesus macaques. AIDS 14: 2445-2455, 2000. |
| |
22. |
A Abimiku, P O'driscoll, J Vertefeuille, N Lar, D Jelpe, P Villalba-Diebold, S Cartier, A Sill1, R Guyit, E Banwat, R Gallo, P Kanki, L Ayuba, W Blattner. HIV Risk Factors Among Antenatal Women in Jos, Nigeria. J Human Virology 5(1): 92, 2002. |
| |
23. |
L Ayuba, J Vertefeuille, P O'driscoll, N Lar, D Jelpe, P Villalba-Diebold, S Cartier, A Sill, R Guyit, E Banwat, R Gallo, P Kanki, W Blattner, A Abimiku. Lack of Understanding of Perinatal Transmission and Prevention among Pregnant Women in Jos Nigeria. Human Virology 5(1): 92, 2002. |
|
| |
Research Interests |
|
| |
Click here to view Dr. Abimiku's Research Interests |
|
